According to the latest statistics of World Health Organization (WHO), the number of people with hearing disabilities in the world has reached 360 million. With the ageing population and the number of hearing-impaired persons increasing year by year, the external otology drugs market shows an increasing trend.

 

Otology drugs for external use can be divided into the following categories:

Otic Compound Steroid Hormone Anti-infective Preparation (for external use)

Otic Anti-infective Drugs (for external use)

Otic Steroid Hormone (for external use)

Others

 

Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, will shed some lights on China’s Import and Export Report of External Use Otology Drugs.

 

I. Global situation of the external otology drugs market

According to the statistics of the World Health Organization (WHO), the global market of external otology drugs in 2015 was approximately 1.024 billion USD, up 11% over the same period of the previous year. 

In addition to this, market sales of Otic Compound Steroid Hormone Anti-infective Preparation (for external use) was 702 million USD with a year-on-year increase of 17%. Market sales of Otic Anti-infective Drugs (for external use) was 143 hundred million USD, with a year-on-year increase of 18% and market sales of Otic Steroid Hormone (for external use) was 45 hundred million USD with an year-on-year decrease of 8%. The market sales of other drug in this category were 134 hundred million USD with a year-on-year decrease of 12%.

 

The sales of Otic Compound Steroid Hormone Anti-infective Preparation (for external use) accounted for the majority share of the global market, exceeding 69%. Below are the sales of the ten leading Otic Compound Steroid Hormone Anti-infective Preparation (for external use):

II. China’s otology drug market

According to the data of PDB, the market size of otology drugs in China in 2016 was 240 million Yuan, of which the market share of external otology drugs was 50 million Yuan, accounting for 20.8% of the total otology drug market.

 

External otology drugs occupied 6 out of the top 10 brands of the otology drug market in China, with the main products being Otic anti-infective drugs (for external use) , of which Levofloxacin ear drops (Shenzhen Wanhe Pharmaceutical) ranked second with a market share of 10.4% .

 

According to an analysis of the external otology drug market in Chinese public hospitals in recent years, the top five domestic manufacturers of external otology drugs are: Shenzhen Wanhe Pharmaceutical, Shanghai Wingguide Huangpu Pharmaceutical, Cisen Pharmaceutical, Wuhan Wujing Medicine and Jiangxi Zhenshiming Pharmaceutical, who occupied more than 95% of the market share of external otology drugs.

The products of these companies are mainly ofloxacin, lomefloxacin and levofloxacin, as well as quinolones which accounted for 98.8% of the domestic market of external otology drugs in public hospitals.

 

III. China’s import of external otology drugs

2016 Market Comparison between Domestic and Imported Otic Drugs (For External Use)

 

At present, locally manufactured otology drugs are more popular than imported ones in China. In regards to the import of external otology drugs, Japan's Santen Pharmaceutical and the ofloxacin ear drops (telbivudine) of Daiichi-Sankyo, occupied a very small market share with the majority of external otology drugs being produced by domestic enterprises.

According to the statistics of PDB, ofloxacin ear drop imports were 0.0036 billion USD in 2016, accounting for 9% of the market.

 

IV.  China’s export of external otology drugs

China's market of ofloxacin ear drops is rapidly developing with product output continuing to increase. With the encouragement of the national industrial policy, China's market will further merge into foreign markets, occupying a large share of exported otology drugs.

 

 

According to statistics of China customs, in 2015, external otology drug exports in China were 1.19 million USD, of which the export of ofloxacin ear drops was 817,700 USD and that of levofloxacin ear drops was 213,500 USD, mainly being exported to India, Pakistan, South Korea and Cambodia.

 

V. Leading companies in the industry

1.  Shenzhen Wanhe Pharmaceutical Co., Ltd

Shenzhen Wanhe Pharmaceutical Co., Ltd. is a high-tech enterprise in China with leading technology in orally disintegrating preparations and controlled-release super mini-pills.

Representative products: levofloxacin hydrochloride ear drops

Main exporting regions: Southeast Asia, Eastern Europe, Latin America.

 

2.  CisenPharmaceutical Co., Ltd

CisenPharmaceutical Co., Ltd is a comprehensive domestic chemical production enterprise, one of China's top 100 pharmaceutical industry enterprises and a national high-tech enterprise.

Representative products: lomefloxacin ear drops, ofloxacin ear drops

Main exporting regions: Pakistan, Angola, Venezuela and Nicaragua

 

3.  Shanghai Winguide Huangpu Pharmaceutical Co.,Ltd

Shanghai Winguide Huangpu Pharmaceutical Co., Ltd is a professional external pharmaceutical company whose production technology has achieved the standard of leading domestic enterprises.

Representative products: ofloxacin ear drops

Main exporting regions: Taiwan

 

VI.  There is a potential market for external otology drugs

In clinical studies on otology, it has been found that most hearing deficits are directly linked to conductive hearing loss, the infection of the ear canal and the lack of timely treatment, especially to otitis media and its related sequelae.

However, otology anti-infective drugs, as an essential medication for otology infections, play an important role in the treatment of suppurative otitis media, earaches, ear pus, tympanic membrane perforation and hearing loss. Ddu, the leading global pharmaceutical & medical device B2B online platform believes that there is a potential market for external otology drugs with people’s increasing awareness of deafness.

Moreover, due to the development of otology anti-infective drugs in the market and limited export diversification of domestic external otology drugs, the current market scale is somewhat restricted, both locally and abroad with the main products being levofloxacin hydrochloride ear drops, ofloxacin ear drops and levofloxacin hydrochloride ear drops.

In conclusion, the improvement of research technology and increasing the variety of external otology drugs will allow for greater opportunities in this market.

 

For more information, please visit: http://cn.media.drugdu.com/

By Ddu